Antisense Compound Modulation of SMN-NAT for SMA Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for spinal muscular atrophy (SMA) are inadequate in effectively increasing the expression of the survival motor neuron (SMN) protein, as the SMN2 gene produces a truncated, unstable version that is inefficient in producing functional SMN protein, leading to severe neurodegenerative symptoms.
Innovation Solution
The use of antisense compounds targeting SMN-NAT, specifically designed to be at least 85% identical to a provided nucleic acid sequence, to increase the expression of SMN protein by reducing SMN-NAT levels, thereby enhancing the production of functional SMN protein in cells and animals.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If SMN2 gene is used to produce SMN protein, then some SMN protein expression is achieved, but the expression level is insufficient (only 10-20% of normal) and the protein is unstable
Solution Approach 1:
The patent uses antisense compounds as intermediaries to modulate the expression of SMN-NAT, which in turn regulates SMN2 gene expression. The antisense compound binds to SMN-NAT transcript, preventing it from interfering with SMN2 gene function, thereby increasing functional SMN protein production without directly modifying the SMN2 gene sequence
Solution Approach 2:
The patent changes the expression parameters of SMN-NAT by introducing antisense compounds that specifically bind to SMN-NAT transcript. This modulates the natural antisense transcript levels, thereby altering the expression balance between functional and non-functional SMN proteins from the SMN2 gene
2Quantity of substance
If antisense compounds targeting SMN-NAT are used, then SMN protein expression increases, but the complexity of the treatment approach increases
Solution Approach 1:
The patent extracts and targets specifically the SMN-NAT transcript as the site of action for antisense compounds. By focusing on this specific element rather than attempting to directly enhance SMN2 gene function, the treatment achievesSMN protein increase through a targeted mechanism that reduces the need for complex multi-component systems
Solution Approach 2:
The antisense compound creates a complementary copy of the SMN-NAT sequence that binds to the endogenous transcript. This molecular copying mechanism allows for specific and potent inhibition of SMN-NAT function, achieving therapeutic effects through a relatively simple single-agent approach
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antisense compounds effectively increase SMN protein expression by up to 120% in cells and subjects with SMA, potentially mitigating the severity of the disease by promoting the production of stable SMN protein.
Implementation Method 1
an antisense compound, which hybridizes to a target nucleic acid, modulates gene expression activities
Data Source
AI summary
Certain embodiments are directed to methods and compounds for inhibiting SMN-NAT, the natural antisense transcript of SMN. Such methods and compounds are useful for increasing expression of SMN in cells and animals.